ReviewAIDS (London, England)2017
HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment.
Review in AIDS (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
149 citing papers in PubMed, 5 syntheses or guidelines pooled it, 250 citations in OpenAlex.
- Risk prediction models for targeted testing of HIV, hepatitis B and hepatitis C: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Skin cancer in patients who are co-infected with HIV/ HBV or HIV/HCV: a systematic review.Archives of dermatological research · 2024Pooled it
- Underestimated Prevalence of HIV, Hepatitis B Virus (HBV), and Hepatitis D Virus (HDV) Triple Infection Globally: Systematic Review and Meta-analysis.JMIR public health and surveillance · 2022Pooled it
- Hepatitis B and hepatitis C prevalence among people living with HIV/AIDS in China: a systematic review and Meta-analysis.Virology journal · 2020Pooled it
- Pooled it
- B/F/TAF in people with both HIV-1 and hepatitis B: outcomes from the ALLIANCE open-label extension phase.AIDS research and therapy · 2026Trial
- Trial
- Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data.Journal of acquired immune deficiency syndromes (1999) · 2024Trial
- Trial
- Hepatitis B, Hepatitis C, tuberculosis and sexually-transmitted infections among HIV positive patients in Kazakhstan.Scientific reports · 2021Trial
- Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection.PloS one · 2019Trial
- Understanding Hepatitis B-Related Knowledge, Attitudes, and Practices Among Nurses of a Selected Tertiary Hospital in Northwestern Bangladesh.Health science reports · 2026Article
- Protocol for a Pilot Quasi-Experimental Study on the Effect of Patient-Centered Education on HIV Virological Outcomes Among Adult People Live With HIV-HBV Co-Infection in North-West Ethiopia: Protocol for a Pilot Quasi-Experimental Study.Health science reports · 2026Article
- Seroprevalence and Early Indicators of HBV and HCV Co-infection Among Newly Diagnosed HIV Patients: A Cross-Sectional Study from India.AIDS and behavior · 2026Article
- Health-related quality of life in adults with hepatitis B in sub-Saharan Africa: the added burden of HIV co-infection.BMC infectious diseases · 2026Observational
- Review
- HIV dominates T-cell immune responses in HIV-HBV co-infection and is associated with increased HIV reservoir transcription.Scientific reports · 2026Article
- HBV Serological Profiles and Vaccination Status in People with HIV in the Transition to a Tenofovir-Sparing Era: Insights from a Large HIV Cohort.Infectious diseases and therapy · 2026Article
- Prevalence of Hepatitis B Coinfection in People With HIV by Birth-Year Cohort.Open forum infectious diseases · 2026Article
- Article
89 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
: HIV infection has a significant impact on the natural history of chronic hepatitis B virus (HBV) infection, with increased levels of HBV DNA, accelerated progression of liver disease and increased liver-associated mortality compared with HBV monoinfection. Widespread uptake and early initiation of HBV-active antiretroviral therapy has substantially improved the natural history of HIV-HBV coinfection but the prevalence of liver disease remains elevated in this population. In this paper, we review recent studies examining the natural history and pathogenesis of liver disease and seroconversion in HIV-HBV coinfection in the era of HBV-active antiretroviral therapy and the effects of HIV directly on liver disease. We also review novel therapeutics for the management of HBV with a particular emphasis on clinical strategies being developed for an HBV cure and an HIV cure and their impact on HIV-HBV coinfected individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.